A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

NCT01745965 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

380

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: T-DM1
DRUG: Trastuzumab

Sponsor

West German Study Group

Collaborators

[object Object]